Phase 1 Recurrent Myelodysplastic/Myeloproliferative Neoplasm Clinical Trials
4 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–4 of 4 trials
Recruiting
Phase 1Phase 2
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Recurrent Chronic Myelomonocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaRecurrent Acute Myeloid Leukemia+3 more
M.D. Anderson Cancer Center97 enrolled1 locationNCT04140487
Recruiting
Phase 1Phase 2
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Refractory Chronic Myelomonocytic LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic/Myeloproliferative Neoplasm+5 more
Uma Borate52 enrolled1 locationNCT06523556
Recruiting
Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Myelodysplastic Syndrome+15 more
M.D. Anderson Cancer Center58 enrolled1 locationNCT03630991
Recruiting
Phase 1
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
Recurrent Chronic Myelomonocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic/Myeloproliferative Neoplasm+3 more
Mayo Clinic25 enrolled1 locationNCT05549661